INOTIV INC
INOTIV Inc (NOTV) is a small-cap contract research organisation that provides preclinical safety, toxicology and bioanalytical services to pharmaceutical and biotechnology clients. With a market capitalisation around $46 million, the company operates in a sector that benefits from drug developers outsourcing complex and regulated testing. Investors should know INOTIV’s revenue depends on client R&D budgets, the timing of project work and regulatory approvals — factors that can cause uneven quarterly results. Potential upside includes steady demand for preclinical services and consolidation in the CRO industry; downside risks include small‑cap liquidity constraints, competition from larger CROs, and sensitivity to biotech funding cycles. This description is educational and not investment advice; performance can vary and investors should review the company’s latest filings, financials and risk disclosures before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INOTIV's stock with a target price of $6.67, indicating strong potential growth.
Financial Health
Inotiv Inc shows moderate revenue and cash flow, but profitability could be improved.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NOTV
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Outsourcing trend tailwind
Pharma and biotech increasingly outsource preclinical testing, which can support demand for INOTIV’s services, though revenue can be uneven by quarter.
Industry positioning matters
A focused CRO can win niche work and partnerships, but competition from larger global players and consolidation are ongoing challenges.
Small-cap considerations
Smaller market cap means potential for higher returns but also greater volatility and liquidity risk; review financials and risk disclosures carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
